Abstract
Driven by the ever-increasing availability of preclinical and clinical Positron Emission Tomography (PET) scanners, the use of non-standard PET nuclides has been growing exponentially in the past decade. Largely complementary to the roles of the four standard PET nuclides (15O, 13N, 11C, and 18F) in PET, non-standard PET nuclides enable the novel design and synthesis of a wider range of PET tracers to probe a variety of biological events. However, characterized by emitting high energy positrons and cascade gamma rays, non-standard PET nuclides with half-lives ranging from seconds to days must be judiciously chosen for specific applications. Generally, chemistries with non-standard PET nuclides are more manageable given a wealth of existing standard operation procedures for the preparation of radiotracers for gamma scintigraphy or Single Photon Emission Computed Tomography (SPECT). This review describes most of the non-standard PET nuclides that have recently been reported for basic PET research or clinical studies with focus on the unique features of their productions, radiochemical procedures, and applications. The main drawbacks of each nuclide are also discussed along with special considerations that must be given towards its practical use in PET.
Keywords: PET, non-standard PET nuclide, imaging probe, immuno-PET, radiation dosimetry, radioimmunoconjugate, molecular imaging
Current Topics in Medicinal Chemistry
Title: PET with Non-Standard Nuclides
Volume: 10 Issue: 11
Author(s): Guiyang Hao, Ajay N Singh, Wei Liu and Xiankai Sun
Affiliation:
Keywords: PET, non-standard PET nuclide, imaging probe, immuno-PET, radiation dosimetry, radioimmunoconjugate, molecular imaging
Abstract: Driven by the ever-increasing availability of preclinical and clinical Positron Emission Tomography (PET) scanners, the use of non-standard PET nuclides has been growing exponentially in the past decade. Largely complementary to the roles of the four standard PET nuclides (15O, 13N, 11C, and 18F) in PET, non-standard PET nuclides enable the novel design and synthesis of a wider range of PET tracers to probe a variety of biological events. However, characterized by emitting high energy positrons and cascade gamma rays, non-standard PET nuclides with half-lives ranging from seconds to days must be judiciously chosen for specific applications. Generally, chemistries with non-standard PET nuclides are more manageable given a wealth of existing standard operation procedures for the preparation of radiotracers for gamma scintigraphy or Single Photon Emission Computed Tomography (SPECT). This review describes most of the non-standard PET nuclides that have recently been reported for basic PET research or clinical studies with focus on the unique features of their productions, radiochemical procedures, and applications. The main drawbacks of each nuclide are also discussed along with special considerations that must be given towards its practical use in PET.
Export Options
About this article
Cite this article as:
Hao Guiyang, N Singh Ajay, Liu Wei and Sun Xiankai, PET with Non-Standard Nuclides, Current Topics in Medicinal Chemistry 2010; 10 (11) . https://dx.doi.org/10.2174/156802610791384289
DOI https://dx.doi.org/10.2174/156802610791384289 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
Current Drug Targets Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment
Current Pharmaceutical Design Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Current Pharmaceutical Design A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Current Drug Targets Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
Current Radiopharmaceuticals The Neurobiological Bases for Development of Pharmacological Treatments of Aggressive Disorders
Current Neuropharmacology ATF4, an ER Stress and Hypoxia-Inducible Transcription Factor and its Potential Role in Hypoxia Tolerance and Tumorigenesis
Current Molecular Medicine A Review on Novel Breast Cancer Therapies: Photodynamic Therapy and Plant Derived Agent Induced Cell Death Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antimicrobial and Structural Properties of Metal Ions Complexes with Thiosemicarbazide Motif and Related Heterocyclic Compounds
Current Medicinal Chemistry Non Pregnant Human Uterus as Source of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Targeted Drug Delivery Via Human Epidermal Growth Factor Receptor for Sustained Release of Allyl Isothiocyanate
Current Topics in Medicinal Chemistry Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics